使用德卡伐替尼治疗口腔扁平苔藓。 - Suppr

Suppr

超能文献

Treatment of oral lichen planus using deucravacitinib.

作者信息

Vu Mindy, Abdin Rama, Issa Naiem T

机构信息

Forefront Dermatology, Vienna, Virginia.

Issa Research and Consulting, LLC, Springfield, Virginia.

出版信息

JAAD Case Rep. 2023 Dec 27;44:94-97. doi: 10.1016/j.jdcr.2023.12.006. eCollection 2024 Feb.

DOI:10.1016/j.jdcr.2023.12.006

PMID:38351970

原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC10861938/

Abstract

摘要

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/cffa/10861938/b4991ed6a36e/gr1.jpg

相似文献

Treatment of oral lichen planus using deucravacitinib.

JAAD Case Rep. 2023 Dec 27;44:94-97. doi: 10.1016/j.jdcr.2023.12.006. eCollection 2024 Feb.

Treatment of hypertrophic lichen planus using deucravacitinib.

JAAD Case Rep. 2024 Jul 5;51:38-40. doi: 10.1016/j.jdcr.2024.06.013. eCollection 2024 Sep.

Janus-kinase inhibitors in dermatology: A review of their use in psoriasis, vitiligo, systemic lupus erythematosus, hidradenitis suppurativa, dermatomyositis, lichen planus, lichen planopilaris, sarcoidosis and graft-versus-host disease.

Indian J Dermatol Venereol Leprol. 2023;90(1):30-40. doi: 10.25259/IJDVL_15_2023.

Nail psoriasis and nail lichen planus: Updates on diagnosis and management.

J Am Acad Dermatol. 2024 Mar;90(3):585-596. doi: 10.1016/j.jaad.2023.11.024. Epub 2023 Nov 24.

Olmutinib Induced Lichen Planus Like Eruption.

Ann Dermatol. 2018 Aug;30(4):451-453. doi: 10.5021/ad.2018.30.4.451. Epub 2018 Jun 27.

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.

Dermatol Ther (Heidelb). 2023 Dec;13(12):3153-3164. doi: 10.1007/s13555-023-01050-7. Epub 2023 Nov 19.

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.

Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30.

Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.

J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165. doi: 10.1177/24755303231201336. Epub 2023 Sep 5.

Study of P21 Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma by Immunohistochemical Technique.

J Dent (Shiraz). 2015 Sep;16(3):156-61.

Assessment of the Role of Vitamin D in the Treatment of Oral Lichen Planus.

J Contemp Dent Pract. 2020 Apr 1;21(4):390-395.

引用本文的文献

A Case of Extensive Lichen Planus Treated With Deucravacitinib.

Cureus. 2024 Oct 20;16(10):e71951. doi: 10.7759/cureus.71951. eCollection 2024 Oct.

本文引用的文献

Targeting Th17 cells: a promising strategy to treat oral mucosal inflammatory diseases.

Front Immunol. 2023 Jul 26;14:1236856. doi: 10.3389/fimmu.2023.1236856. eCollection 2023.

The potential roles of Th17 cells in the pathogenesis of oral lichen planus.

Inflamm Res. 2023 Jul;72(7):1513-1524. doi: 10.1007/s00011-023-01763-7. Epub 2023 Jul 6.

Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.

Dermatol Ther (Heidelb). 2023 Feb;13(2):417-435. doi: 10.1007/s13555-022-00878-9. Epub 2023 Jan 2.

Therapeutic strategies for oral lichen planus: State of the art and new insights.

Front Med (Lausanne). 2022 Oct 4;9:997190. doi: 10.3389/fmed.2022.997190. eCollection 2022.

JAK inhibitors in lichen planus: a review of pathogenesis and treatments.

J Dermatolog Treat. 2022 Dec;33(8):3098-3103. doi: 10.1080/09546634.2022.2116926. Epub 2022 Aug 29.

Potential role of INTERLEUKIN-17 in the pathogenesis of oral lichen planus: a systematic review with META-analysis.

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1735-1744. doi: 10.1111/jdv.18219. Epub 2022 May 24.

Immune mechanisms in oral lichen planus.

Oral Dis. 2023 May;29(4):1400-1415. doi: 10.1111/odi.14142. Epub 2022 Feb 8.

Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus.

Front Immunol. 2019 Jul 31;10:1808. doi: 10.3389/fimmu.2019.01808. eCollection 2019.

Overexpression and selectively regulatory roles of IL-23/IL-17 axis in the lesions of oral lichen planus.

Mediators Inflamm. 2014;2014:701094. doi: 10.1155/2014/701094. Epub 2014 Jul 8.

Possible role of interleukin-17 in the pathogenesis of lichen planus.

Br J Dermatol. 2012 Jun;166(6):1367-8. doi: 10.1111/j.1365-2133.2011.10793.x. Epub 2012 Mar 14.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验

相似文献

Treatment of oral lichen planus using deucravacitinib.

JAAD Case Rep. 2023 Dec 27;44:94-97. doi: 10.1016/j.jdcr.2023.12.006. eCollection 2024 Feb.

Treatment of hypertrophic lichen planus using deucravacitinib.

JAAD Case Rep. 2024 Jul 5;51:38-40. doi: 10.1016/j.jdcr.2024.06.013. eCollection 2024 Sep.

Indian J Dermatol Venereol Leprol. 2023;90(1):30-40. doi: 10.25259/IJDVL_15_2023.

Nail psoriasis and nail lichen planus: Updates on diagnosis and management.

J Am Acad Dermatol. 2024 Mar;90(3):585-596. doi: 10.1016/j.jaad.2023.11.024. Epub 2023 Nov 24.

Olmutinib Induced Lichen Planus Like Eruption.

Ann Dermatol. 2018 Aug;30(4):451-453. doi: 10.5021/ad.2018.30.4.451. Epub 2018 Jun 27.

Pharmacokinetics and Safety of the Tyrosine Kinase 2 Inhibitor Deucravacitinib in Healthy Chinese Subjects.

Dermatol Ther (Heidelb). 2023 Dec;13(12):3153-3164. doi: 10.1007/s13555-023-01050-7. Epub 2023 Nov 19.

Selectivity Profile of the Tyrosine Kinase 2 Inhibitor Deucravacitinib Compared with Janus Kinase 1/2/3 Inhibitors.

Dermatol Ther (Heidelb). 2021 Oct;11(5):1763-1776. doi: 10.1007/s13555-021-00596-8. Epub 2021 Aug 30.

Deucravacitinib: a novel TYK2 inhibitor for the treatment of moderate-to-severe psoriasis.

J Psoriasis Psoriatic Arthritis. 2023 Oct;8(4):156-165. doi: 10.1177/24755303231201336. Epub 2023 Sep 5.

Study of P21 Expression in Oral Lichen Planus and Oral Squamous Cell Carcinoma by Immunohistochemical Technique.

J Dent (Shiraz). 2015 Sep;16(3):156-61.

Assessment of the Role of Vitamin D in the Treatment of Oral Lichen Planus.

J Contemp Dent Pract. 2020 Apr 1;21(4):390-395.

引用本文的文献

A Case of Extensive Lichen Planus Treated With Deucravacitinib.

Cureus. 2024 Oct 20;16(10):e71951. doi: 10.7759/cureus.71951. eCollection 2024 Oct.

本文引用的文献

Targeting Th17 cells: a promising strategy to treat oral mucosal inflammatory diseases.

Front Immunol. 2023 Jul 26;14:1236856. doi: 10.3389/fimmu.2023.1236856. eCollection 2023.

The potential roles of Th17 cells in the pathogenesis of oral lichen planus.

Inflamm Res. 2023 Jul;72(7):1513-1524. doi: 10.1007/s00011-023-01763-7. Epub 2023 Jul 6.

Novel Therapies in Plaque Psoriasis: A Review of Tyrosine Kinase 2 Inhibitors.

Dermatol Ther (Heidelb). 2023 Feb;13(2):417-435. doi: 10.1007/s13555-022-00878-9. Epub 2023 Jan 2.

Therapeutic strategies for oral lichen planus: State of the art and new insights.

Front Med (Lausanne). 2022 Oct 4;9:997190. doi: 10.3389/fmed.2022.997190. eCollection 2022.

JAK inhibitors in lichen planus: a review of pathogenesis and treatments.

J Dermatolog Treat. 2022 Dec;33(8):3098-3103. doi: 10.1080/09546634.2022.2116926. Epub 2022 Aug 29.

Potential role of INTERLEUKIN-17 in the pathogenesis of oral lichen planus: a systematic review with META-analysis.

J Eur Acad Dermatol Venereol. 2022 Oct;36(10):1735-1744. doi: 10.1111/jdv.18219. Epub 2022 May 24.

Immune mechanisms in oral lichen planus.

Oral Dis. 2023 May;29(4):1400-1415. doi: 10.1111/odi.14142. Epub 2022 Feb 8.

Therapeutic Targeting of Th17/Tc17 Cells Leads to Clinical Improvement of Lichen Planus.

Front Immunol. 2019 Jul 31;10:1808. doi: 10.3389/fimmu.2019.01808. eCollection 2019.

Overexpression and selectively regulatory roles of IL-23/IL-17 axis in the lesions of oral lichen planus.

Mediators Inflamm. 2014;2014:701094. doi: 10.1155/2014/701094. Epub 2014 Jul 8.

Possible role of interleukin-17 in the pathogenesis of lichen planus.

Br J Dermatol. 2012 Jun;166(6):1367-8. doi: 10.1111/j.1365-2133.2011.10793.x. Epub 2012 Mar 14.